STZ/HFD mice receiving the eNAMPT-neutralizing ALT-100 mAb (weeks 9–12) exhibited significant decreases in NAFLD activity scores, liver triglycerides, plasma eNAMPT, IL-6, and TNFα levels, with reduced hepatic injury (hepatocyte ballooning) and fibrosis (Sirius staining) compared to untreated STZ/HFD mice. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.